Dermatology Times
@DermTimesNow
Followers
32K
Following
3K
Media
7K
Statuses
22K
A leading news resource serving dermatology clinicians.
North Olmsted, Ohio
Joined July 2009
💡 At #EADV2025, Emma Guttman-Yassky, MD, PhD, shared breakthrough data on #ritlecitinib, a JAK3/TEC inhibitor showing promise across 3 types of scarring #alopecia. https://t.co/A0Dd6cZHlV
#DermTwitter
dermatologytimes.com
A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.
0
0
0
💬👥 Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin is redefining clinical trials with a community-based, multisite model that boosts diversity, access, and real-world relevance in dermatology research. https://t.co/yGECqUgsPP
#DermTwitter
dermatologytimes.com
Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Skin’s mission to make research more representative and accessible through integrated, multisite dermatology practices.
0
0
1
💡 Amy Lewis, MD spotlights the Glo2Facial: a 4-in-1 device boosting skin health with internal oxygenation, RF, ultrasound & massage. https://t.co/y3JWuRdbIm
#DermTwitter #Aesthetics
dermatologytimes.com
Discover how the Glo2Facial revolutionizes aesthetic dermatology with innovative skin oxygenation and customizable treatments for radiant, youthful skin.
0
1
5
👥 At #PDPA2025, Nicholas Brownstone, MD, tackles boxed warnings in his session, exploring whether they reflect real risk or just regulatory caution. https://t.co/5Z3dU2usDb
#DermTwitter
dermatologytimes.com
Brownstone’s PDPA session explores how class labeling and insufficient data can mislead clinicians and alarm patients unnecessarily.
0
0
1
📚 A Chinese study links #rosacea to smoking, alcohol, sun exposure, cosmetics, and dairy, plus higher rates of depression and impaired quality of life. https://t.co/MV1JmG8tTb
#DermTwitter
dermatologytimes.com
New research highlights the psychosocial impact of rosacea on Chinese patients, linking lifestyle factors and comorbidities to quality of life.
0
0
5
📰 Radiation dermatitis affects up to 95% of patients on radiation therapy, impacting quality of life and treatment continuity. New guidelines and emerging therapies aim to improve prevention, management, and outcomes. https://t.co/umuJkLOXqb
#OncoDerm #DermTwitter
dermatologytimes.com
Radiation dermatitis significantly affects breast cancer patients, impacting quality of life and treatment. Discover effective prevention and management strategies.
0
0
4
⭐️ In a recent Community Case Forum event, Anthony Nuara, MD, PhD, emphasized a patient-centered approach to #psoriasis, highlighting real-world challenges, evolving therapies, and the importance of tailoring treatment. https://t.co/NfHQ60kZh2
#DermTwitter
dermatologytimes.com
Explore real-world psoriasis management insights from Anthony Nuara, MD, PhD, focusing on patient-centered approaches and innovative treatments like tildrakizumab.
0
0
0
📈 A large RCT found that combining 308 nm Excimer laser with oral JAK inhibitors significantly improved repigmentation and disease stability in localized non-segmental #vitiligo vs. monotherapy. https://t.co/Wh4O5zxHzZ
#DermTwitter
dermatologytimes.com
A new trial reveals that combining Excimer laser with JAK inhibitors significantly enhances vitiligo treatment outcomes, ensuring safety and durability.
0
0
5
💡 Lawrence Eichenfield, MD, highlights the FDA’s new approval of #roflumilast 0.05% cream for kids 2+ as a major step in #AD care—offering fast, safe, steroid-free relief for families wary of long-term corticosteroid use. https://t.co/XbVZxA0w8c
#PediatricDerm #DermTwitter
dermatologytimes.com
The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.
0
0
0
📚 #Vitiligo patients show high rates of depression, anxiety, and stress, but physical activity was not linked to improved psychological outcomes. https://t.co/qIkTicsYdg
#DermTwitter
dermatologytimes.com
Findings suggest that physical activity alone may not meet the psychosocial needs of vitiligo patients, emphasizing the need for targeted mental health care.
0
0
1
📚 A new 5-year study finds most #isotretinoin adverse effects are skin-related and often dose-dependent, including xerosis, cheilitis, and chronic hand eczema. https://t.co/TUmnnYXk2j
#Acne #CHE #DermTwitter
dermatologytimes.com
New research highlights the link between isotretinoin dosage and increased chronic hand eczema, emphasizing the need for careful monitoring during acne treatment.
0
0
2
💡 Emma Guttman-Yassky, MD, PhD, provided insights into the emerging biologic #APG777 (Apogee Therapeutics), with its potential for extended dosing intervals and favorable safety profile in atopic dermatitis. https://t.co/K4V3FdfyYy
#AtopicDerm #DermTwitter
0
0
2
📰 Christopher G. Bunick, MD, PhD, highlights the growing clinical role of dermatology in breast cancer care and research in the October issue. https://t.co/sOxMzv6oit
#BreastCancerAwarenessMonth #DermTwitter
dermatologytimes.com
Dermatologists play a crucial role in breast cancer care, enhancing patient outcomes through early detection and innovative research on keratin-targeting therapies.
0
0
5
📚 In this week's edition of the #JournalDigest, we review the latest dermatological insights including mitigating irritation from 0.1% retinol, OTC therapies for alopecia, the perception of skin lesions in the delivery room, and more. https://t.co/GrucDE0TBn
#DermTwitter
dermatologytimes.com
This review of the latest dermatologic studies highlights new research on mitigating irritation from 0.1% retinol, OTC therapies for alopecia, the perception of skin lesions by HCPs in the delivery...
0
0
0
📈 The IPC’s updated #psoriasis guidelines shift from rigid BSA cutoffs to a more patient-centered model, defining systemic therapy candidates by high-impact site involvement or topical failure. https://t.co/0I8PE0QfBH
#DermTwitter
dermatologytimes.com
Discover the latest IPC consensus on psoriasis severity reclassification, enhancing treatment strategies for better patient outcomes and quality of life.
0
0
1
📈 #Delgocitinib 2% cream shows strong efficacy and safety in chronic hand #eczema, with rapid itch and pain relief, durable responses, and minimal systemic absorption. https://t.co/9sR1n4ZwUO
#CHE #DermTwitter
dermatologytimes.com
Delgocitinib showed consistent efficacy in atopic, irritant, allergic, and hyperkeratotic forms of chronic hand eczema in pooled trial data.
0
0
7
💡 Michael Chancellor, MD, discussed LP-10, a liposomal #tacrolimus rinse that showed significant clinical improvement and minimal systemic absorption in a phase 2a trial for oral lichen planus. https://t.co/UUQWBoXg0J
#LichenPlanus #OLP #DermTwitter
dermatologytimes.com
Lipella Pharmaceuticals' LP-10 shows promise as a targeted treatment for OLP, offering safety and efficacy in recent trials, according to Michael Chancellor, MD.
0
0
1
👥 At #EADV2025, researchers unveiled #VDPHL01, an extended-release oral #minoxidil showing 4x greater hair regrowth vs. current options in 4 months. This new formulation could mark a major breakthrough in androgenetic #alopecia treatment. https://t.co/d3upuOYJ5q
#DermTwitter
dermatologytimes.com
The investigational extended-release tablet maintained therapeutic plasma levels while avoiding peaks linked to cardiovascular risk.
1
0
7
📰 This #BreastCancerAwarenessMonth, discover how dermatologists play a vital role in early detection, diagnosis, and managing treatment-related skin issues, highlighting the power of cross-specialty collaboration in improving patient care. https://t.co/CngBSuiToN
#DermTwitter
dermatologytimes.com
Explore the vital role of dermatology in breast cancer care, from early detection to managing skin issues related to treatment and radiation.
0
0
2
💡 #Dupilumab shows early, sustained efficacy in chronic spontaneous urticaria (#CSU), offering a new option for patients unresponsive to antihistamines. https://t.co/hJuJumIHBo
#DermTwitter
dermatologytimes.com
Quality of life improvements paralleled clinical efficacy in the CUPID studies of dupilumab.
0
0
3